Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

NSG mice as hosts for oncological precision medicine.

Maletzki C, Bock S, Fruh P, Macius K, Witt A, Prall F, Linnebacher M.

Lab Invest. 2019 Aug 13. doi: 10.1038/s41374-019-0298-6. [Epub ahead of print]

PMID:
31409886
2.

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer.

Lazzari L, Corti G, Picco G, Isella C, Montone M, Arcella P, Durinikova E, Zanella ER, Novara L, Barbosa F, Cassingena A, Cancelliere C, Medico E, Sartore-Bianchi A, Siena S, Garnett MJ, Bertotti A, Trusolino L, Di Nicolantonio F, Linnebacher M, Bardelli A, Arena S.

Clin Cancer Res. 2019 Aug 2. doi: 10.1158/1078-0432.CCR-18-3440. [Epub ahead of print]

PMID:
31375513
3.

Human Colorectal Carcinoma Infiltrating B Lymphocytes Are Active Secretors of the Immunoglobulin Isotypes A, G, and M.

Mullins CS, Gock M, Krohn M, Linnebacher M.

Cancers (Basel). 2019 Jun 4;11(6). pii: E776. doi: 10.3390/cancers11060776.

4.

Targeting Immune-Related Molecules in Cancer Therapy: A Comprehensive In Vitro Analysis on Patient-Derived Tumor Models.

Maletzki C, Scheinpflug P, Witt A, Klar E, Linnebacher M.

Biomed Res Int. 2019 Feb 12;2019:4938285. doi: 10.1155/2019/4938285. eCollection 2019.

5.

AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro.

Lange F, Weßlau K, Porath K, Hörnschemeyer J, Bergner C, Krause BJ, Mullins CS, Linnebacher M, Köhling R, Kirschstein T.

PLoS One. 2019 Feb 4;14(2):e0211644. doi: 10.1371/journal.pone.0211644. eCollection 2019.

6.

Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens.

Wagner S, Mullins CS, Linnebacher M.

World J Gastroenterol. 2018 Dec 28;24(48):5418-5432. doi: 10.3748/wjg.v24.i48.5418. Review.

7.

Establishment, functional and genetic characterization of three novel patient-derived rectal cancer cell lines.

Gock M, Mullins CS, Bergner C, Prall F, Ramer R, Göder A, Krämer OH, Lange F, Krause BJ, Klar E, Linnebacher M.

World J Gastroenterol. 2018 Nov 21;24(43):4880-4892. doi: 10.3748/wjg.v24.i43.4880.

8.

Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line.

Gock M, Mullins CS, Harnack C, Prall F, Ramer R, Göder A, Krämer OH, Klar E, Linnebacher M.

World J Gastroenterol. 2018 Sep 7;24(33):3749-3759. doi: 10.3748/wjg.v24.i33.3749.

9.

Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells.

Rauch A, Carlstedt A, Emmerich C, Mustafa AM, Göder A, Knauer SK, Linnebacher M, Heinzel T, Krämer OH.

Oncotarget. 2018 Jun 12;9(45):27835-27850. doi: 10.18632/oncotarget.25600. eCollection 2018 Jun 12.

10.

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

Russo M, Lamba S, Lorenzato A, Sogari A, Corti G, Rospo G, Mussolin B, Montone M, Lazzari L, Arena S, Oddo D, Linnebacher M, Sartore-Bianchi A, Pietrantonio F, Siena S, Di Nicolantonio F, Bardelli A.

Nat Commun. 2018 Jun 12;9(1):2287. doi: 10.1038/s41467-018-04506-z.

11.

Murine Endogenous Retroviruses Are Detectable in Patient-Derived Xenografts but Not in Patient-Individual Cell Lines of Human Colorectal Cancer.

Bock S, Mullins CS, Klar E, Pérot P, Maletzki C, Linnebacher M.

Front Microbiol. 2018 Apr 24;9:789. doi: 10.3389/fmicb.2018.00789. eCollection 2018.

12.

β-catenin-independent regulation of Wnt target genes by RoR2 and ATF2/ATF4 in colon cancer cells.

Voloshanenko O, Schwartz U, Kranz D, Rauscher B, Linnebacher M, Augustin I, Boutros M.

Sci Rep. 2018 Feb 16;8(1):3178. doi: 10.1038/s41598-018-20641-5.

13.

Cellular vaccination of MLH1-/- mice - an immunotherapeutic proof of concept study.

Maletzki C, Gladbach YS, Hamed M, Fuellen G, Semmler ML, Stenzel J, Linnebacher M.

Oncoimmunology. 2017 Dec 14;7(3):e1408748. doi: 10.1080/2162402X.2017.1408748. eCollection 2018.

14.

Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.

William D, Walther M, Schneider B, Linnebacher M, Classen CF.

PLoS One. 2018 Jan 19;13(1):e0191511. doi: 10.1371/journal.pone.0191511. eCollection 2018.

15.

Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer.

Rohde S, Lindner T, Polei S, Stenzel J, Borufka L, Achilles S, Hartmann E, Lange F, Maletzki C, Linnebacher M, Glass Ä, Schwarzenböck SM, Kurth J, Hohn A, Vollmar B, Krause BJ, Jaster R.

Oncotarget. 2017 Jul 15;8(41):69756-69767. doi: 10.18632/oncotarget.19263. eCollection 2017 Sep 19.

16.

Colorectal carcinoma tumour budding and podia formation in the xenograft microenvironment.

Prall F, Maletzki C, Hühns M, Krohn M, Linnebacher M.

PLoS One. 2017 Oct 17;12(10):e0186271. doi: 10.1371/journal.pone.0186271. eCollection 2017.

17.

Deciphering molecular mechanisms of arginine deiminase-based therapy - Comparative response analysis in paired human primary and recurrent glioblastomas.

Maletzki C, Rosche Y, Riess C, Scholz A, William D, Classen CF, Kreikemeyer B, Linnebacher M, Fiedler T.

Chem Biol Interact. 2017 Dec 25;278:179-188. doi: 10.1016/j.cbi.2017.10.007. Epub 2017 Oct 5.

PMID:
28989041
18.

Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme.

William D, Mokri P, Lamp N, Linnebacher M, Classen CF, Erbersdobler A, Schneider B.

PLoS One. 2017 Sep 21;12(9):e0185208. doi: 10.1371/journal.pone.0185208. eCollection 2017.

19.

Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.

Wiegering A, Matthes N, Mühling B, Koospal M, Quenzer A, Peter S, Germer CT, Linnebacher M, Otto C.

Neoplasia. 2017 Apr;19(4):301-309. doi: 10.1016/j.neo.2017.01.007. Epub 2017 Mar 9.

20.

Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair-deficiency and Lynch syndrome.

Maletzki C, Huehns M, Bauer I, Ripperger T, Mork MM, Vilar E, Klöcking S, Zettl H, Prall F, Linnebacher M.

Mol Carcinog. 2017 Jul;56(7):1753-1764. doi: 10.1002/mc.22632. Epub 2017 Mar 30.

PMID:
28218421
21.

Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies.

William D, Mullins CS, Schneider B, Orthmann A, Lamp N, Krohn M, Hoffmann A, Classen CF, Linnebacher M.

J Transl Med. 2017 Feb 9;15(1):27. doi: 10.1186/s12967-017-1128-5.

22.

Tumor Take Rate Optimization for Colorectal Carcinoma Patient-Derived Xenograft Models.

Gock M, Kühn F, Mullins CS, Krohn M, Prall F, Klar E, Linnebacher M.

Biomed Res Int. 2016;2016:1715053. doi: 10.1155/2016/1715053. Epub 2016 Nov 23.

23.

Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells.

Schäfer C, Göder A, Beyer M, Kiweler N, Mahendrarajah N, Rauch A, Nikolova T, Stojanovic N, Wieczorek M, Reich TR, Tomicic MT, Linnebacher M, Sonnemann J, Dietrich S, Sellmer A, Mahboobi S, Heinzel T, Schneider G, Krämer OH.

Cell Signal. 2017 Jan;29:218-225. doi: 10.1016/j.cellsig.2016.11.002. Epub 2016 Nov 9.

PMID:
27838375
24.

Generation of Xenotransplants from Human Cancer Biopsies to Assess Anti-cancer Activities of HDACi.

Mullins CS, Bock S, Krohn M, Linnebacher M.

Methods Mol Biol. 2017;1510:217-229.

PMID:
27761824
25.

The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis.

Maletzki C, Beyrich F, Hühns M, Klar E, Linnebacher M.

Oncotarget. 2016 Aug 16;7(33):53583-53598. doi: 10.18632/oncotarget.10677.

26.

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F.

Cancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16.

27.

Generation, Characterization and Application of Antibodies Directed against HERV-H Gag Protein in Colorectal Samples.

Mullins CS, Hühns M, Krohn M, Peters S, Cheynet V, Oriol G, Guillotte M, Ducrot S, Mallet F, Linnebacher M.

PLoS One. 2016 Apr 27;11(4):e0153349. doi: 10.1371/journal.pone.0153349. eCollection 2016.

28.

After Intestinal Transplantation Kidney Function Is Impaired by Downregulation of Epithelial Ion Transporters in the Ileum.

Reiner J, Hsieh CJ, Straarup C, Bodammer P, Schäffler H, Graepler F, Stüker D, Kratt T, Linnebacher M, Nadalin S, Witte M, Königsrainer A, Lamprecht G.

Transplant Proc. 2016 Mar;48(2):499-506. doi: 10.1016/j.transproceed.2015.12.068.

PMID:
27109987
29.

Establishment and characterization of HROC69 - a Crohn´s related colonic carcinoma cell line and its matched patient-derived xenograft.

Kuehn F, Mullins CS, Krohn M, Harnack C, Ramer R, Krämer OH, Klar E, Huehns M, Linnebacher M.

Sci Rep. 2016 Apr 18;6:24671. doi: 10.1038/srep24671.

30.

Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype.

Maletzki C, Huehns M, Knapp P, Waukosin N, Klar E, Prall F, Linnebacher M.

PLoS One. 2015 Nov 30;10(11):e0143194. doi: 10.1371/journal.pone.0143194. eCollection 2015.

31.

Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes.

Pérot P, Mullins CS, Naville M, Bressan C, Hühns M, Gock M, Kühn F, Volff JN, Trillet-Lenoir V, Linnebacher M, Mallet F.

Oncotarget. 2015 Nov 24;6(37):40095-111. doi: 10.18632/oncotarget.5539.

32.

Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.

Schellhorn M, Haustein M, Frank M, Linnebacher M, Hinz B.

Oncotarget. 2015 Nov 17;6(36):39342-56. doi: 10.18632/oncotarget.5745.

33.

Optimizing the process of nucleofection for professional antigen presenting cells.

Mullins CS, Wegner T, Klar E, Classen CF, Linnebacher M.

BMC Res Notes. 2015 Sep 24;8:472. doi: 10.1186/s13104-015-1446-8.

34.

Stage-specific frequency and prognostic significance of aneuploidy in patients with sporadic colorectal cancer--a meta-analysis and current overview.

Laubert T, Freitag-Wolf S, Linnebacher M, König A, Vollmar B, Habermann JK; North German Tumorbank of Colorectal Cancer (ColoNet) consortium.

Int J Colorectal Dis. 2015 Aug;30(8):1015-28. doi: 10.1007/s00384-015-2259-x. Epub 2015 Jun 9. Review.

PMID:
26054386
35.

Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks.

Ahmad-Nejad P, Duda A, Sucker A, Werner M, Bronsert P, Stickeler E, Reifenberger G, Malzkorn B, Oberländer M, Habermann JK, Bruch HP, Linnebacher M, Schadendorf D, Neumaier M.

Clin Chem Lab Med. 2015 Nov;53(12):1927-34. doi: 10.1515/cclm-2014-1202.

PMID:
26053008
36.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F, Bardelli A.

Nat Commun. 2015 Apr 30;6:7002. doi: 10.1038/ncomms8002.

37.

Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.

Fiedler T, Strauss M, Hering S, Redanz U, William D, Rosche Y, Classen CF, Kreikemeyer B, Linnebacher M, Maletzki C.

Cancer Biol Ther. 2015;16(7):1047-55. doi: 10.1080/15384047.2015.1026478. Epub 2015 Mar 16.

38.

MicroRNA-mRNA interactions in colorectal cancer and their role in tumor progression.

Amirkhah R, Schmitz U, Linnebacher M, Wolkenhauer O, Farazmand A.

Genes Chromosomes Cancer. 2015 Mar;54(3):129-41. doi: 10.1002/gcc.22231. Review.

PMID:
25620079
39.

Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease.

Kuehn F, Klar E, Bliemeister A, Linnebacher M.

World J Gastroenterol. 2015 Jan 7;21(1):221-8. doi: 10.3748/wjg.v21.i1.221.

40.

Establishment and characterization of cell lines from chromosomal instable colorectal cancer.

Maletzki C, Gock M, Randow M, Klar E, Huehns M, Prall F, Linnebacher M.

World J Gastroenterol. 2015 Jan 7;21(1):164-76. doi: 10.3748/wjg.v21.i1.164.

41.

E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.

Wiegering A, Korb D, Thalheimer A, Kämmerer U, Allmanritter J, Matthes N, Linnebacher M, Schlegel N, Klein I, Ergün S, Germer CT, Otto C.

Neoplasia. 2014 Nov 20;16(11):972-81. doi: 10.1016/j.neo.2014.09.008. eCollection 2014 Nov.

42.

Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.

Lange F, Franz B, Maletzki C, Linnebacher M, Hühns M, Jaster R.

Biomed Res Int. 2014;2014:568693. doi: 10.1155/2014/568693. Epub 2014 Sep 17.

43.

Accounting for randomness in measurement and sampling in studying cancer cell population dynamics.

Ghavami S, Wolkenhauer O, Lahouti F, Ullah M, Linnebacher M.

IET Syst Biol. 2014 Oct;8(5):230-41. doi: 10.1049/iet-syb.2013.0031.

PMID:
25257023
44.

Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.

Haustein M, Ramer R, Linnebacher M, Manda K, Hinz B.

Biochem Pharmacol. 2014 Nov 15;92(2):312-25. doi: 10.1016/j.bcp.2014.07.014. Epub 2014 Jul 25.

PMID:
25069049
45.

The impact of pyrvinium pamoate on colon cancer cell viability.

Wiegering A, Uthe FW, Hüttenrauch M, Mühling B, Linnebacher M, Krummenast F, Germer CT, Thalheimer A, Otto C.

Int J Colorectal Dis. 2014 Oct;29(10):1189-98. doi: 10.1007/s00384-014-1975-y. Epub 2014 Jul 26.

PMID:
25060218
46.

Host defense peptides for treatment of colorectal carcinoma - a comparative in vitro and in vivo analysis.

Maletzki C, Klier U, Marinkovic S, Klar E, Andrä J, Linnebacher M.

Oncotarget. 2014 Jun 30;5(12):4467-79.

47.

PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: two hits on the gene?

Hühns M, Salem T, Schneider B, Krohn M, Linnebacher M, Prall F.

Oncol Rep. 2014 May;31(5):2236-44. doi: 10.3892/or.2014.3097. Epub 2014 Mar 19.

PMID:
24647592
48.

Combinations of TLR ligands: a promising approach in cancer immunotherapy.

Stier S, Maletzki C, Klier U, Linnebacher M.

Clin Dev Immunol. 2013;2013:271246. doi: 10.1155/2013/271246. Epub 2013 Nov 25.

49.

Microsatellite instability in hematological malignancies: Hypermutation vs. immune control-who is challenging who?

Maletzki C, Stier S, Linnebacher M.

Oncoimmunology. 2013 Aug 1;2(8):e25419. Epub 2013 Jul 1.

50.

Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison.

Mullins CS, Schneider B, Stockhammer F, Krohn M, Classen CF, Linnebacher M.

PLoS One. 2013 Aug 7;8(8):e71070. doi: 10.1371/journal.pone.0071070. eCollection 2013.

Supplemental Content

Loading ...
Support Center